FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

With a new chief at the helm and higher profit projections in sight, AbbVie is entering a “new chapter," CEO Robert Michael told analysts Thursday. During the second quarter, AbbVie reported a 29.8% ...

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is ...

Does CRC Risk in IBD Extend to Close Family Members? Close relatives of people with IBD are not at increased risk for CRC, strengthening the theory that it's the inflammation or atypia of the colon ...

IBD Rates Rising in Canada's Youngest Children The incidence of inflammatory bowel disease in children aged 5 years and younger has risen by 7.2% per year between 1999 and 2010, a new study has found.

AbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster drug ...

WASHINGTON, Aug 24 (Reuters) - Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on ...